Skip to main content
. Author manuscript; available in PMC: 2015 Dec 28.
Published in final edited form as: J Control Release. 2014 Oct 24;0:272–286. doi: 10.1016/j.jconrel.2014.10.016

Fig. 15.

Fig. 15

In vivo antitumor activity of varying DOX formulations in a drug-resistant xenograft tumor model, KB 8-5. Solid arrows indicate the i.v. injection. A: relative tumor volume. *p < 0.002, compared to PEG5K-Fmoc-VE2/DOX (5 mg/kg); & p < 0.01, compared to PEG5K-VE2/DOX (5 mg/kg); # p < 0.05, compared to DOX (7.5 mg/kg); € p < 0.05, compared to DOX (5 mg/kg) or saline. B: body weight, α p < 0.0005, compared to day 1; β p < 0.005, compared to day 1; £ p < 0.05, compared to day 1. C: tumor images. D: tumor weight, *p < 0.005, compared to PEG5K-Fmoc-VE2/DOX (5 mg/kg); & p < 0.01, compared to PEG5K-VE2/DOX (5 mg/kg); # p < 0.001, compared to DOX (7.5 mg/kg); € p < 0.05, compared to DOX (5 mg/kg).